SPT Energy Group Inc. — Proxy Solicitation & Information Statement 2026

Jan 14, 2026

{0}------------------------------------------------

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED

(Incorporated in Hong Kong with limited liability) (Stock Code: 570)

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the "EGM") of China Traditional Chinese Medicine Holdings Co. Limited (the "Company") will be held at Conference Room, 4th floor, Winteam Plaza, 6 Kuiqi Second Road, Chancheng District, Foshan City, Guangdong Province, China on Monday, 2 February 2026 at 2:30 p.m., for the purposes of considering and, if thought fit, passing the following ordinary resolutions (with or without modifications):

ORDINARY RESOLUTIONS

To consider and, if thought fit, pass the following resolutions (with or without modification) as ordinary resolutions of the Company:

1. "THAT:

• (a) the Financial Services (2026-2028) Framework Agreement (as defined in the circular of the Company dated 15 January 2026 (the "Circular")) dated 25 November 2025 and entered into between the Company and Sinopharm Group Finance Co., Ltd. ("Sinopharm Group Finance"), a copy of which is tabled at the EGM and marked "A" and initialled by the Chairman of the EGM for identification purpose, in relation to provision of a range of financial services by Sinopharm Group Finance to the Company and its subsidiaries (collectively, the "Group") and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;
• (b) the annual caps for the Financial Services (2026-2028) Framework Agreement and the transactions contemplated thereunder as stated in the Circular for the three years ending 31 December 2028 be and are hereby approved, confirmed and ratified; and

{1}------------------------------------------------

(c) any one or more of the directors of the Company (the "Directors") be and is/are hereby authorised to do all such acts and things and execute all such documents which he/she/ they consider necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to the Financial Services (2026-2028) Framework Agreement and the transactions contemplated thereunder and to waive compliance from or make and agree such variations of a non-material nature to any of the terms of the Financial Services (2026-2028) Framework Agreement as they may in his/her/their discretion consider to be desirable and in the interests of the Company and all the Directors' acts as aforesaid be hereby approved, confirmed and ratified."

2. "THAT:

• (a) the Master Purchase (2026-2028) Agreement (as defined in the Circular) dated 25 November 2025 and entered into between the Company and China National Pharmaceutical Group Co., Ltd. ("CNPGC"), a copy of which is tabled at the EGM and marked "B" and initialled by the Chairman of the EGM for identification purpose, in relation to the purchases of traditional Chinese medicine and chemical materials and services from CNPGC and its subsidiaries (collectively, the "CNPGC Group") and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;
• (b) the annual caps for the Master Purchase (2026-2028) Agreement and the transactions contemplated thereunder as stated in the Circular for the three years ending 31 December 2028 be and are hereby approved, confirmed and ratified; and
• (c) any one or more of the Directors be and is/are hereby authorised to do all such acts and things and execute all such documents which he/she/they consider necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to the Master Purchase (2026-2028) Agreement and the transactions contemplated thereunder and to waive compliance from or make and agree such variations of a nonmaterial nature to any of the terms of the Master Purchase (2026-2028) Agreement as they may in his/her/their discretion consider to be desirable and in the interests of the Company and all the Directors' acts as aforesaid be hereby approved, confirmed and ratified."

3. "THAT:

(a) the Master Supply (2026-2028) Agreement (as defined in the Circular) dated 25 November 2025 and entered into between the Company and CNPGC, a copy of which is tabled at the EGM and marked "C" and initialled by the Chairman of the EGM for identification purpose, in relation to the sales of various pharmaceutical products manufactured and supplied by the Group and provide leasing services to the CNPGC Group and the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;

{2}------------------------------------------------

• (b) the annual caps for the Master Supply (2026-2028) Agreement and the transactions contemplated thereunder as stated in the Circular for the three years ending 31 December 2028 be and are hereby approved, confirmed and ratified; and
• (c) any one or more of the Directors be and is/are hereby authorised to do all such acts and things and execute all such documents which he/she/they consider necessary, desirable or expedient for the purpose of, or in connection with, the implementation of and giving effect to the Master Supply (2026-2028) Agreement and the transactions contemplated thereunder and to waive compliance from or make and agree such variations of a nonmaterial nature to any of the terms of the Master Supply (2026-2028) Agreement as they may in his/her/their discretion consider to be desirable and in the interests of the Company and all the Directors' acts as aforesaid be hereby approved, confirmed and ratified."

By Order of the Board China Traditional Chinese Medicine Holdings Co. Limited YANG Jun

Chairman

Hong Kong, 15 January 2026

Notes:

• 1. In order to determine the Shareholders who are entitled to attend the EGM, the Company's register of members will be closed from Wednesday, 28 January 2026 to Monday, 2 February 2026 (both days inclusive). The Shareholders whose names appear on the register of members of the Company on Monday, 2 February 2026 are entitled to attend and vote at the EGM. Shareholders who wish to attend the EGM but have not registered the transfer documents are required to deposit the transfer documents together with the relevant share certificates at the registrar of the Company in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong no later than 4:30 p.m. on Tuesday, 27 January 2026.
• 1. Any member of the Company entitled to attend and vote at the EGM shall be entitled to appoint another person as his/her proxy to attend and vote instead of him/her. A member who is the holder of two or more shares may appoint more than one proxy to represent him/her and vote on his/her behalf at the EGM. A proxy need not be a member of the Company.
• 1. A form of proxy for the EGM is enclosed. The instrument appointing a proxy and the power of attorney or other authority, if any, under which it is signed, or a certified copy of such power or authority, shall be deposited at the Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong as soon as possible and in any event not less than 48 hours before the time appointed for holding the EGM.

As at the date of this notice, the Board comprises twelve Directors, of which Mr. YANG Jun, Mr. LI Hongjian and Mr. PENG Li are executive Directors; Mr. LIU Haijian, Mr. LI Xiangrong, Mr. ZU Jing, Ms. XU Jinghui and Mr. HUANG Hao are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.